Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.42 |
| ▸ | CD69 | Q07108 | 1/20 | 0.42 |
| ▸ | SLC28A3 | Q9HAS3 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27921424 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| SCHEMBL8648898 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| SCHEMBL19475556 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| SCHEMBL460988 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| SCHEMBL7094225 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| SCHEMBL2413753 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| SCHEMBL25166887 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| SCHEMBL1898656 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| Hydrochloric Acid SCHEMBL28256651 | 0.98 | LMNA (0.42) | LMNAKDM4EALOX15LGALS8CD69 | |
| Ammonia Solution, Strong SCHEMBL27636528 | 0.98 | LMNA (0.42) | LMNAKDM4EALOX15LGALS8CD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381246-A1 | LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES | 89BIO, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250333460-A1 | MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES AND USES THEREOF | 89BIO LTD. (IL) | 2025-10-30 | — | — | US | disclosed |
| US-20250282840-A1 | METHODS OF TREATMENT USING MUTANT FGF-21 PEPTIDE CONJUGATES | 89BIO LTD. (IL) | 2025-09-11 | — | — | US | disclosed |
| US-12350314-B2 | Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates | 89BIO, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4577563-A2 | METHODS OF TREATMENT OF NASH USING MUTANT FGF-21 PEPTIDE CONJUGATES | 89Bio, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025043155-A1 | THERAPEUTIC REGIMENS AND METHODS OF TREATMENT OF NASH USING MUTANT FGF-21 PEPTIDE CONJUGATES | 89BIO, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20240307492-A1 | LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES | 89BIO, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| US-12037376-B2 | Methods of treatment using mutant FGF-21 peptide conjugates | 89BIO LTD. (IL) | 2024-07-16 | — | — | US | disclosed |
| US-20240116995-A1 | MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES AND USES THEREOF | 89BIO LTD. (IL) | 2024-04-11 | — | — | US | disclosed |
| WO-2024044680-A2 | METHODS OF TREATMENT OF NASH USING MUTANT FGF-21 PEPTIDE CONJUGATES | 89BIO, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2005070138-A2 | O-LINKED GLYCOSYLATION OF PEPTIDES | NEOSE TECHNOLOGIES, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050143292-A1 | Glycopegylated erythropoietin | NOVO NORDISK A/S (DK) | 2005-06-30 | — | — | US | disclosed |
| WO-2005055946-A2 | GLYCOPEGYLATED GRANULOCYTE COLONY STIMULATING FACTOR | NEOSE TECHNOLOGIES, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005055950-A2 | GLYCOPEGYLATED FACTOR IX | NEOSE TECHNOLOGIES, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005051327-A2 | GLYCOPEGYLATED ERYTHROPOIETIN | NEOSE TECHNOLOGIES, INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005012484-A2 | ANTIBODY-TOXIN CONJUGATES | NEOSE TECHNOLOGIES, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2004103275-A2 | COMPOSITIONS AND METHODS FOR THE PREPARATION OF HUMAN GROWTH HORMONE GLYCOSYLATION MUTANTS | NEOSE TECHNOLOGIES, INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004091499-A2 | INTRACELLULAR FORMATION OF PEPTIDE CONJUGATES | NEOSE TECHNOLOGIES, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004083258-A2 | BRANCHED WATER-SOLUBLE POLYMERS AND THEIR CONJUGATES | NEOSE TECHNOLOGIES INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| CN-85107911-A | The production method of ellipticine derivative | — | 1987-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12350314-B2 | Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates | FGF1, FGFR1, FGF2 | LMNA 4219/4885KDM4E 4725/4885ALOX15 1117/4885 |
| US-20250282840-A1 | METHODS OF TREATMENT USING MUTANT FGF-21 PEPTIDE CONJUGATES | HDGF, FGF1, FGFR1 | LMNA 3715/4885KDM4E 4314/4885ALOX15 2894/4885 |
| US-20250381246-A1 | LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES | FGF1, FGFR1, FGF2 | LMNA 4219/4885KDM4E 4725/4885ALOX15 1117/4885 |
| US-20250333460-A1 | MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES AND USES THEREOF | FGF1, FGF2, FGF23 | LMNA 4316/4885KDM4E 3911/4885ALOX15 3315/4885 |
| US-20240116995-A1 | MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES AND USES THEREOF | FGF1, FGF2, FGF23 | LMNA 4316/4885KDM4E 3911/4885ALOX15 3315/4885 |
| US-20050143292-A1 | Glycopegylated erythropoietin | EPOR, UGGT1, GNE | LMNA 2220/4885KDM4E 2672/4885ALOX15 1826/4885 |
| US-20240307492-A1 | LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES | FGF1, FGFR1, FGF2 | LMNA 4219/4885KDM4E 4725/4885ALOX15 1117/4885 |
| US-12037376-B2 | Methods of treatment using mutant FGF-21 peptide conjugates | HDGF, FGF1, FGFR1 | LMNA 3715/4885KDM4E 4314/4885ALOX15 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.